Trial Profile

A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bermekimab (Primary)
Indications Atopic dermatitis
Focus Adverse reactions; Proof of concept
Sponsors XBiotech

Most Recent Events

30 Aug 2024 Results published in the Archives of Dermatological Research
12 Nov 2019 According to a XBiotech media release, data from this trial were presented at the European Academy of Dermatology and Venereology (EADV) Congress
27 Sep 2019 Results presented in the XBiotech media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com